FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures

FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Kah Keng, Gascoyne, Duncan M., Soilleux, Elizabeth J., Lyne, Linden, Spearman, Hayley, Roncador, Giovanna, Pedersen, Lars M., Møller, Michael B., Green, Tina M., Banham, Alison H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/
https://www.ncbi.nlm.nih.gov/pubmed/27224915
http://dx.doi.org/10.18632/oncotarget.9507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/
https://www.ncbi.nlm.nih.gov/pubmed/27224915
http://dx.doi.org/10.18632/oncotarget.9507

Ejemplares similares